Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 25, Art. 4 (pp. 49-70)    |    2024       

»

Promising approaches to overcoming antibiotic resistance

Yudin M.A.1, Stepanov A.V.1, Bogacheva A.S.2, Sventickaya A.M.1, Bykova K.A.1

1 State Scientific Research Testing Institute of Military Medicine of the Ministry of Defense of the Russian Federation, 195043, Saint Petersburg, Lesoparkovaya st. 4
2North-Western State Medical University named after I.I. Mechnikov. Russia, 191015, Saint-Petersburg, Kirochnaya street, 41

Brief summary

In recent years, there has been an increase in bacterial resistance on a global scale due to the active uncontrolled use of antibiotics. Numerous studies report the antibacterial activity of non-steroidal anti-inflammatory drugs, local anaesthetics, phenothiazines such as chlorpromazine, levomepromazine, promethazine, trifluoperazine, methdilazine and thioridazine, antidepressants, antiplatelets and statins. In order to stop the spread of antibiotic resistance, many researchers propose to change the traditional approach to drug antimicrobial therapy, namely, to use drugs that do not have direct antimicrobial activity. Numerous studies report the antibacterial activity of non-steroidal anti-inflammatory drugs, local anaesthetics, phenothiazines such as chlorpromazine, levomepromazine, promethazine, trifluoperazine, methdilazine and thioridazine, antidepressants, antiplatelets and statins. This is extremely important both for infectious diseases and for the national security of the country, since the attention of biopathogens with pronounced resistance to antibiotics is many times more important for society than conventional research.


Key words

antimicrobial agents; non-steroidal anti-inflammatory drugs; antidepressants; opioids; statins; antihistamines

Reference list

1. Opal S.M. Non-antibiotic treatments for bacterial diseases in an era of progressive antibiotic resistance. Critical Care. 2016; 20: 1-3. https://doi.org/10.1186/s13054-016-1549-1.


2. Silva, A., Silva, P.M. Non-Antibiotic Compounds: The Activity of the NSAID Diclofenac on Bacteria - a review. International Journal of Current Microbiology and Applied Sciences. 2018; 7: 340-351. https://doi.org/10.20546/IJCMAS.2018.712.042.


3. Nugrahani I., Herawati D., Wibowo M.S. The Benefits and Challenges of Antibiotics-non-steroidal anti-inflammatory drugs non-covalent reaction Molecules. 2023; 28(9): 3672. https://doi.org/10.3390/molecules28093672.


4. Chockattu S. J., Deepak B.S., Goud K.M. Comparison of anti-bacterial efficiency of ibuprofen, diclofenac, and calcium hydroxide against Enterococcus faecalis in an endodontic model: an in vitro study. Journal of conservative dentistry. 2018; 21(1): 80-84. https://doi.org/10.4103/JCD.JCD_349_16.


5. Razavi B.M., Fazly Bazzaz B.S. A review and new insights to antimicrobial action of local anesthetics. European Journal of Clinical Microbiology & Infectious Diseases. 2019; 38(6): 991-1002. https://doi.org/10.1007/s10096-018-03460-44.


6. Barbarossa A., Rosato A., Corbo F., Clodoveo M. L., Fracchiolla G., Carrieru A., Carocci A. Non-antibiotic drug repositioning as an alternative antimicrobial approach. Antibiotics. 2022; 11(6): 816. https://doi.org/10.3390/antibiotics11060816.


7. Ivanov D. G., Afonkina E. A., Lisenko U.N., Hromov R. N., Nikiforov A. S., Sybbotina S. N., Sitnikov D. K. Doklinicheskii skrining effektivnosti i bezopasnosti κ-opiatnih analgetikov na osnove ih neirotoksicheskogo profilya. Medlain.ry. - 2023; 24: 166-175.


8. Ceccato A. Safety considerations of current drug treatment strategies for nosocomial pneumonia / A. Ceccato, P. Di Giannatale, S. Nogas, A. Torres // Expert Opinion on Drug Safety. - 2021. - Vol. 20. - ? 2. - pp. 181-190. https://doi.org/10.1080/14740338.2021.1857362.


9. Anderson D.B., Shaheed C.A. Medications for treating low back pain in adults. Evidence for the use of paracetamol, opioids, nonsteroidal anti-inflammatories, muscle relaxants, antibiotics and antidepressants. An Overview for Musculoskeletal Clinicians. Journal of Orthopaedic and Sports Physical Therapy. 2022; 52(7): 425-431. https://www.jospt.org/doi/10.2519/jospt.2022.10788.


10. Altice F.L., Azbel L., Stone J., Brooks-Pollock E., Smyrnov P., Dvoriak S. The perfect storm: incarceration and the high-risk environment perpetualing transmission of HIV, hepatitis C, and tuberculosis in Easterm Europe and Central Asia. The Lancet. 2016; 388(10050): 1228-1248. https://doi.org/10.1016/S0140-6736(16)30856-X.


11. Abdel Shaheed C., Beardsley J., Day R.O., McLachlan A. J. Immunomodulatory effects of pharmaceutical opioids and antipyretic analgesics: Mechanisms and relevance to infection. British Pharmacological Society Journals. 2022; 88(7): 3114-3131. https://doi.org/10.1111/bcp.15281.


12. Racz B., Spengler G. Repurposing Antidepressants and Phenothiazine Antipsychotics as Efflux Pump inhibitors in Cancer and infectious Diseases. Antibiotics (Basel). 2023; 12(1): 137. https://doi.org/10.3390/antibiotics12010137.


13. Prestinaci F., Pezzotti P., Pantosti A. Antimicrobial Resistance: A Global Multifaceted Phenomenon. Pathogens and global health. 2015; 109: 309-318. https://doi.org/10.1179/2047773215Y.0000000030.


14. Marinov M., Spengler G. Phenothiazine derivatives of 1, 8-naphthalic anhydride: Synthesis, characterization and antimicrobial studies. Phosphorus, Sulfur, and Silicon and the Related Elements. 2023; 198(2): 128-136. https://doi.org/10.3390/antibiotics12010137.


15. Andersson J.A., Fitts E.C., Kirtley M.L. New role for FDA-approved drugs in combating antibiotic-resistant bacteria. Antimicrobial agents and chemotherapy. 2016; 60: 3717-3729. https://doi.org/10.1128/aac.00326.


16. Caldara M., Graziano S., Gulli M. Off-target effects of neuroleptics and antidepressants on saccharomyces cerevisiae. Toxicological Sciences. 2017; 156: 538-548. https://doi.org/10.1093/toxsci/kfx007.


17. Ait Chait Y., Mottawea W., Tompkins T.A., Hammani R. Unravelling the antimicrobial action of antidepressants on gut commensal microbes. Scientific reports. 2020; 10: 1-11. https://doi.org/10.1038/s41598-020-74934-9.


18. Dalhoff A. Are antibacterial effects of non-antibiotic drugs random or purposeful because of a common evolutionary origin of bacterial and mammalian targets. Infection. 2021; 49(4): 569-589. https://doi.org/10.1007/s15010-020-01547-9.


19. Kalayci S., Demirci S., Sahin F. Antimicrobial Properties of Various Psychotropic Drugs Against Broad Range Microorganisms. Current Psychopharmacology. 2015; 3: 195-202.


20. Sjostedt P., Enander J., Isung J. Serotonin Reuptake Inhibitors and the Gut Microbiome: Significance of the Gut Microbiome in Relation to Mechanism of Action, Treatment, Side Effects, and Tachyphylaxis. Frontiers in Psychiatry. 2021; 12: 682868. https://doi.org/10.3389/fpsyt.2021.682868.


21. Ueda R., Kataoka H. The potential of the antiplatelet agent ticagrelor as a new antibacterial agent. Revista Médica de Risaralda. 2023; 29(1): 147-156. https://doi.org/10.22517/25395203.25126.


22. Jean S-S., Hsueh S-C, Hwang J-J, Hsueh P-R. Ticagrelor: A promising role in preventing multi-organ failure among patients with sepsis due to resistant gram-positive cocci. Journal of microbiology, immunology, and infection. 2019; 52: 513-515. https://doi.org/10.1016/j.jmii.2019.06.0044.


23. Mehboob S., Parween S., Saleem D., Tabussum S. In vitro interaction studies of levocetirizine with cimetidine. IJBPAS. 2019; 8: 518-527.


24. Kruszewska H., Zareba T., Tyski S. Examination of antimicrobial activity of selected non-antibiotic medical preparations. Poloniae Pharmaceutica. 2012; 69(6): 1368-1371.


25. Numata, M., Kandasamy P., Voelker D.R. The anti-inflammatory and antiviral properties of anionic pulmonary surfactant phospholipids. Immunological Reviews. 2023; 317(1): 166-186. https://doi.org/10.1111/imr.13207.